AstraZeneca's Antiplatelet Agent Brilinta Superior To Plavix In Phase III Trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Importantly for AstraZeneca's antithrombotic portfolio, the company's single Phase III trial for the investigational antiplatelet therapy Brilinta (ticagrelor) was a success - showing superior efficacy over Sanofi Aventis/Bristol-Myers Squibb's Plavix (clopidogrel) in a head-to-head comparison